--- title: "Delta Sleep-Inducing Peptide (DSIP)" canonical_url: https://bestpeptidecalculator.app/library/dsip description: "Nonapeptide first isolated from the cerebral venous blood of rabbits during induced slow-wave sleep and named for that association. Its physiological role remains genuinely unsettled: no specific receptor has been identified, reported effects on sleep architecture are inconsistent across studies, and its ability to cross the blood-brain barrier is debated. Research use only and not FDA-approved." updated: 2026-09-26 publisher: Peptide Library notice: "Research and educational use only. Not medical advice." --- # Delta Sleep-Inducing Peptide (DSIP) Delta Sleep-Inducing Peptide (DSIP), also called Emideltide or Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu, is a neuropeptide research in the Neuromodulator class. Delta sleep-inducing peptide is a nonapeptide first isolated from the cerebral venous blood of rabbits during induced slow-wave sleep, and named for that association. Nonapeptide first isolated from the cerebral venous blood of rabbits during induced slow-wave sleep and named for that association. Its physiological role remains genuinely unsettled: no specific receptor has been identified, reported effects on sleep architecture are inconsistent across studies, and its ability to cross the blood-brain barrier is debated. Research use only and not FDA-approved. Also known as: Emideltide, Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu. Categories: Cognitive, Longevity, Experimental. ## Classification - Type: Sleep / neuropeptide research - Mechanism class: Neuromodulator - Development stage: Research only - Regulatory class: Research compound, not FDA-approved ## Mechanism Delta sleep-inducing peptide is a nonapeptide first isolated from the cerebral venous blood of rabbits during induced slow-wave sleep, and named for that association. Its physiological role remains genuinely unsettled: no specific receptor has been identified, reports of its effect on sleep architecture are inconsistent across studies, and its ability to cross the blood-brain barrier after peripheral administration is debated. Proposed activities include modulation of GABAergic transmission, influence on circadian and neuroendocrine rhythms including corticotropin and growth hormone release, and stress-buffering effects. For a reference entry the honest position is that the peptide is real and studied but its mechanism is not established. Targets: Sleep-regulatory networks (proposed). Origin: Synthetic nonapeptide corresponding to delta sleep-inducing peptide. ## Properties - Sequence: Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu - Length: 9 - Molecular formula: C35H48N10O15 - Molecular weight: 848.81 g/mol - CAS number: 62568-57-4 - Half-life: ~7-15 minutes - Studied routes: Intravenous ## Evidence - Evidence level: Limited Human Evidence - Highest documented: Controlled human trials - Human trials: 4 - Controlled human trials: 2 - Preclinical sources: 0 - Latest source: 2009 Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess. ### Studies 1. Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients. Neuropsychobiology. 1992. 1992. Controlled human trial. Population: Chronic insomniac patients. Sleep architecture [Source](https://pubmed.ncbi.nlm.nih.gov/1299794/) 2. Delta sleep-inducing peptide administration does not influence growth hormone and prolactin secretion. Psychoneuroendocrinology. 1993. 1993. Controlled human trial. Population: Human volunteers. Growth hormone and other endocrine responses — no influence found [Source](https://pubmed.ncbi.nlm.nih.gov/8475226/) 3. Delta sleep-inducing peptide alters bispectral index, the electroencephalogram and heart rate variability when used as an adjunct to isoflurane anaesthesia. Eur J Anaesthesiol. 2009. 2009. Human study (early or uncontrolled). Population: Surgical patients. Bispectral index and electroencephalogram changes [Source](https://pubmed.ncbi.nlm.nih.gov/19142086/) 4. Opioid detoxification with delta sleep-inducing peptide: results of an open clinical trial. J Clin Psychopharmacol. 1998. 1998. Human study (early or uncontrolled). Population: Patients undergoing opioid detoxification. Withdrawal symptoms [Source](https://pubmed.ncbi.nlm.nih.gov/9617990/) ## Safety Side effects: Headache; Vivid dreams (anecdotal); Unknown chronic safety. Risks: Not an approved hypnotic. Contraindications: Psychiatric disorders. Human safety basis: Limited human reports Key limitations: Not approved by the FDA for any use.. ## Regulatory status Delta Sleep-Inducing Peptide (DSIP) is not an FDA-approved product. It is sold for laboratory research and has no approved medical use. - FDA status: Not Approved - Availability: Research-Only ## Frequently asked questions ### What is Delta Sleep-Inducing Peptide (DSIP)? Nonapeptide first isolated from the cerebral venous blood of rabbits during induced slow-wave sleep and named for that association. Its physiological role remains genuinely unsettled: no specific receptor has been identified, reported effects on sleep architecture are inconsistent across studies, and its ability to cross the blood-brain barrier is debated. Research use only and not FDA-approved. ### What are the side effects of Delta Sleep-Inducing Peptide (DSIP)? Delta Sleep-Inducing Peptide (DSIP) has only limited human data, so its side-effect profile is not well established. Effects recorded on this profile include headache and vivid dreams (anecdotal). Cautions recorded on this profile: psychiatric disorders. This is reference information, not medical advice. ### How does Delta Sleep-Inducing Peptide (DSIP) work? Delta sleep-inducing peptide is a nonapeptide first isolated from the cerebral venous blood of rabbits during induced slow-wave sleep, and named for that association. Its physiological role remains genuinely unsettled: no specific receptor has been identified, reports of its effect on sleep architecture are inconsistent across studies, and its ability to cross the blood-brain barrier after peripheral administration is debated. ### Is Delta Sleep-Inducing Peptide (DSIP) FDA approved? No. Delta Sleep-Inducing Peptide (DSIP) is not approved by the FDA for any indication and is categorised as research-only. It has not been reviewed for safety or efficacy as a medicine, and published research should be read as investigation rather than established use. FDA's compounding lists show 503A nomination: Previously in Category 2; nomination withdrawn by the nominators. ### What is the half-life of Delta Sleep-Inducing Peptide (DSIP)? Reported half-life for Delta Sleep-Inducing Peptide (DSIP) is ~7-15 minutes. Half-life describes how long the compound persists in circulation, not how long any effect lasts, and published figures vary with route of administration, formulation and the population studied. ### What is the amino acid sequence of Delta Sleep-Inducing Peptide (DSIP)? Delta Sleep-Inducing Peptide (DSIP) has the sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu, giving a chain of 9 amino acids. Its molecular formula is C35H48N10O15. ### What peptides are similar to Delta Sleep-Inducing Peptide (DSIP)? Compounds most often compared with Delta Sleep-Inducing Peptide (DSIP) include Orexin-A, Epitalon, N-Acetyl Selank Amidate and Noopept. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ. ### Does DSIP work as a sleep aid? Not reliably, on current evidence. DSIP was named in the 1970s after rabbit experiments associated it with delta-wave sleep, and the name has outrun the data: human sleep findings have been inconsistent, and it is not established as a sleep-inducing agent. The name describes what its discoverers were looking for, not a demonstrated effect. ### Does DSIP cross the blood-brain barrier? Poorly, like most peptides, which matters for a compound expected to act on sleep. Recent research includes delivery strategies and fusion constructs designed to get DSIP into the brain in rodent insomnia models. That the delivery problem is still being worked on says a lot about how unsettled the basic effect is. ### Is DSIP related to melatonin? No. Melatonin is a hormone made from tryptophan in the pineal gland; DSIP is a nine-amino-acid peptide. They are different molecules acting through different systems, and DSIP is not a melatonin analogue or precursor. ## References - [Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients. A double-blind study — Neuropsychobiology, 1992](https://pubmed.ncbi.nlm.nih.gov/1299794/) - [Different effects of delta-sleep-inducing peptide on arginine-vasopressin and ACTH secretion in normal men — Horm Res, 1994](https://pubmed.ncbi.nlm.nih.gov/7698722/) - [Delta sleep-inducing peptide (DSIP): a still unresolved riddle — J Neurochem, 2006](https://pubmed.ncbi.nlm.nih.gov/16539679/) - [Effects of delta-sleep-inducing peptide on 24-hour sleep-wake behaviour in severe chronic insomnia — Eur Neurol, 1987](https://pubmed.ncbi.nlm.nih.gov/3622582/) - [Study of delta sleep-inducing peptide efficacy in improving sleep on short-term administration to chronic insomniacs — Int J Clin Pharmacol Res, 1987](https://pubmed.ncbi.nlm.nih.gov/3583493/) Note: Dose figures are left out of this Markdown version. See the cited sources.